Back to search

Peptide record

TPDB40945

LvHemB1 Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40945
LvHemB1
Anticancer
Cancer-related peptides
CancerPPD 2.0 dbACP
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and dbACP, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-DVNFLLHKIYGNIRY-NH2
Physicochemical Analysis
C88H133N23O22
ACEQMPSTW
NILY
1865.16
9.56
3
1
8
+1
0.16
-0.100
123.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: >10 hour
2980
159.77
4
Residue Composition
number
0
A
1
R
2
N
1
D
0
C
0
E
0
Q
1
G
1
H
2
I
2
L
1
K
0
M
1
F
0
P
0
S
0
T
0
W
2
Y
1
V
Amino Acid Distribution
A: 0 R: 1 N: 2 D: 1 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 2 L: 2 K: 1 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 2 V: 1
Chemical Descriptors
15
C88H133N23O22
1865.16
9.56
+1
0.16
-0.100
Amidation
L
Linear
Acetylation
Antimicrobial
hemocyanin of Litopenaeus vannamei
Evidence Records 4 records
Evidence 1 Activity

Activity

65.1% apoptotic cells at 50 µg/mL
Anticancer

Target

Cervical cancer
HeLa
Cervix

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

57.1% apoptotic cells at 50 µg/mL
Anticancer

Target

Esophageal Cancer
EC-109
Esophagus

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 3 Activity

Activity

44.2% apoptotic cells at 50 µg/mL
Anticancer

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 4 Activity

Activity

89.6% apoptotic cells at 50 µg/mL
Anticancer

Target

Bladder Cancer
EJ
Bladder

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022